立即打开
疫苗公司的政府合同被解除,股价腰斩

疫苗公司的政府合同被解除,股价腰斩

Sophie Mellor 2021年09月16日
英国政府表示,由于Valneva违反了协议规定的义务,因此终止与该公司的合同。

英国政府取消了从法国生物科技公司Valneva购买1亿剂新冠疫苗的订单,导致该公司的股价暴跌45%。这款疫苗目前已经进入后期临床试验。

英国政府表示,由于Valneva违反了协议规定的义务,因此终止与该公司的合同,但Valneva “坚决”否认这种指控。这笔订单价值高达14亿欧元(约合16.5亿美元),原定于在苏格兰生产疫苗,并从2022年开始交付。

Valneva的股价在巴黎早盘交易中暴跌超过40%,跌至11欧元,之后有所反弹。

Valneva与目前市场上的其他新冠疫苗的区别在于,它能够刺激对完整的灭活新冠病毒的免疫反应,而不是仅针对刺突蛋白产生反应。有科学家表示这款疫苗可以针对更多变种病毒提供保护。

这种传统的疫苗设计以灭活病毒样本刺激免疫反应,这意味着Valneva的疫苗能够作为现有疫苗的补充,用作加强针,正是这个有吸引力的特点使Valneva的股价在过去一年内翻了两番。

目前尚不确定英国政府宣布取消订单的具体原因,但Valneva之前曾经警告由于供应链问题,在欧盟(EU)和英国之间出口疫苗存在“严重风险”。

目前这款疫苗仍然在进行后期试验,预计将在今年第四季度公布试验结果。实验室曾经在8月底表示,根据1期和2期临床试验的结果,这款疫苗的有效率有望超过80%。预计这款疫苗将在明年晚些时候获得英国的批准。

Valneva在一份声明中表示:“公司一直在尽最大努力与英国政府合作,包括投入大量资源和精力响应英国政府对变种病毒疫苗的要求。”

早在今年4月,Valneva与欧盟委员会(European Commission)的谈判同样以失败告终,因为欧盟高层表示,该公司达不到“某些特定的条件”。据媒体报道,Valneva优先处理英国订单是双方谈判失败的原因之一。

随后,双方在6月底恢复谈判,这表明欧盟已经不再将此视为障碍,但Valneva并没有获得欧盟的购买协议。该公司一直在与欧盟各国单独谈判疫苗合同。(财富中文网)

译者:刘进龙

审校:汪皓

英国政府取消了从法国生物科技公司Valneva购买1亿剂新冠疫苗的订单,导致该公司的股价暴跌45%。这款疫苗目前已经进入后期临床试验。

英国政府表示,由于Valneva违反了协议规定的义务,因此终止与该公司的合同,但Valneva “坚决”否认这种指控。这笔订单价值高达14亿欧元(约合16.5亿美元),原定于在苏格兰生产疫苗,并从2022年开始交付。

Valneva的股价在巴黎早盘交易中暴跌超过40%,跌至11欧元,之后有所反弹。

Valneva与目前市场上的其他新冠疫苗的区别在于,它能够刺激对完整的灭活新冠病毒的免疫反应,而不是仅针对刺突蛋白产生反应。有科学家表示这款疫苗可以针对更多变种病毒提供保护。

这种传统的疫苗设计以灭活病毒样本刺激免疫反应,这意味着Valneva的疫苗能够作为现有疫苗的补充,用作加强针,正是这个有吸引力的特点使Valneva的股价在过去一年内翻了两番。

目前尚不确定英国政府宣布取消订单的具体原因,但Valneva之前曾经警告由于供应链问题,在欧盟(EU)和英国之间出口疫苗存在“严重风险”。

目前这款疫苗仍然在进行后期试验,预计将在今年第四季度公布试验结果。实验室曾经在8月底表示,根据1期和2期临床试验的结果,这款疫苗的有效率有望超过80%。预计这款疫苗将在明年晚些时候获得英国的批准。

Valneva在一份声明中表示:“公司一直在尽最大努力与英国政府合作,包括投入大量资源和精力响应英国政府对变种病毒疫苗的要求。”

早在今年4月,Valneva与欧盟委员会(European Commission)的谈判同样以失败告终,因为欧盟高层表示,该公司达不到“某些特定的条件”。据媒体报道,Valneva优先处理英国订单是双方谈判失败的原因之一。

随后,双方在6月底恢复谈判,这表明欧盟已经不再将此视为障碍,但Valneva并没有获得欧盟的购买协议。该公司一直在与欧盟各国单独谈判疫苗合同。(财富中文网)

译者:刘进龙

审校:汪皓

The U.K. government has canceled its order of 100 million doses of the late-stage COVID-19 vaccine from France-based biotech firm Valneva—leading company shares to plummet by 45%.

The U.K. government said it had terminated the contract because Valneva was in breach of its obligations under the deal—a claim Valneva “strenuously” denies. The deal was worth up to 1.4 billion ($1.65 billion) with the vaccine set to be manufactured in Scotland. Deliveries were expected to start in 2022.

Shares in Valneva fell more than 40% in early Paris trading, hitting a low of 11 before recouping some of the losses.

The Valneva vaccine differentiates itself from the vaccines currently on the market by stimulating a reaction to the inactivated whole COVID-19 virus, rather than just targeting the spike protein, a process that some scientists say should offer protection against more variants.

This old-school vaccine design of taking a killed sample of the disease and using it to stimulate an immune response means the Valneva shot could complement existing vaccines and be used as a booster shot—an attractive feature that has helped Valvena quadruple its stock price over the past year.

It is not clear what pushed the U.K. government to serve a notice of termination, but in previous warnings, Valneva warned of a “substantial risk” to exporting the vaccine between the EU and the U.K. owing to supply chain issues.

The vaccine is currently still in late-stage trials with the results expected in the fourth quarter of this year. The laboratory noted at the end of August that based on Phase I and Phase II trials, it hoped to have a vaccine that is more than 80% effective. U.K. approval is slated for late next year.

“Valneva has worked tirelessly, and to its best efforts, on the collaboration with HMG including investing significant resources and effort to respond to HMG’s requests for variant-derived vaccines,” the company said in a statement.

Back in April, talks between Valneva and the European Commission also broke down because, the EU executive said, the company failed to meet “a certain set of conditions.” Valneva’s prioritization of the U.K.’s order was reportedly a factor.

There was a subsequent resurrection of the talks in late June, suggesting the EU no longer saw this as an obstacle, but Valneva never secured an EU purchase agreement. It has been negotiating vaccine contracts on a country-by-country basis.

最新:
  • 热读文章
  • 热门视频
活动
扫码打开财富Plus App
##########
<pre id='deFSat'><span></span></pre>
    <sup id='LRTqQYN'><big></big></sup>
      <bgsound id='PyxDV'><basefont></basefont></bgsound><caption id='kJ'><option></option></caption>
        <tt id='BfWoHQZ'><del></del></tt><nobr id='ept'><var></var></nobr>
        <basefont id='pNMTIP'><blockquote></blockquote></basefont><listing id='kvFNXH'><listing></listing></listing>
        <b id='DOg'><bdo></bdo></b><span id='hMG'><tt></tt></span>